Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

NeuroClues: the clinical must-have for Neurologists: clinical validation, industrialization, and go-to-market.

Project description

Medical device for accurate movement disorder diagnosis

NeuroClues is a groundbreaking portable, fast, and easy-to-use eye-tracking medical device that integrates clinically validated eye movement biomarkers for movement disorders (MDs) into neurologists’ clinical routines. With this in mind, the EIC-funded NeuroClues project aims to help neurologists make faster and more accurate diagnoses, reducing the diagnostic timeline from months to days and enabling earlier patient care. The project will validate NeuroClues’ integration into clinical practice with key opinion leader neurologists and assess its clinical value through ongoing studies in the EU and US. This validation is essential for gaining widespread acceptance among neurologists. Successful demonstration, combined with a strong go-to-market strategy, will position the developer, P3Lab, to be investor-ready by 2024 and profitable by 2027.

Objective

P3Lab developed NeuroClues, a first-of-a-kind portable, fast and easy to use eye tracking medical device that brings clinically validated eye movement biomarkers for movement disorders (MDs) into the clinical routine of neurologists. NeuroClues will enable neurologists to establish their MD diagnosis faster (from months to days) earlier and more reliably, and with diagnostic grade accuracy. This will enable neurologists to start patient care earlier. This project aims at validating and demonstrating (I) the usability of NeuroClues in the clinical routine with early adopter KOL neurologists and (II) assess its clinical value in ongoing and (III) in own sponsored clinical investigation studies (EU and US). This is needed to convince the broad majority of neurologist of NeuroClues’ clinical value. The successful demonstration and accompanied development of our go-to-market strategy will enable P3Lab to become investor ready by 2024 and profitable by 2027, with €70M ARR targeted by 2030.

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

P3 LAB
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 500 000,00
Address
RUE DU MORIMONT 33
1341 OTTIGNIES-LOUVAIN-LA-NEUVE
Belgium

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Région wallonne Prov. Brabant Wallon Arr. Nivelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 5 557 786,50
My booklet 0 0